Akers Biosciences Inc. Akers Biosciences, Inc. engages in the development, manufacture, and supply of screening and testing products. Its products include clinical diagnostics and safety tests. Akers Biosciences Inc. all SEC filings breakout by MarketWatch. View the AKER U.S. Securities and Exchange Commission reporting information. Stock analysis for Akers Biosciences Inc (AKER:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. * AKERS BIOSCIENCES INC FILES FOR OFFER OF UP TO 793,437 SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILING Source text: (https://bit.ly/2ZstE7n) Further company coverage: BRIEF-Akers Akers Biosciences Inc. annual stock financials by MarketWatch. View the latest AKER financial statements, income statements and financial ratios. Akers Biosciences (AKER) reports earnings on 8/14/2020. The Earnings Whisper Score gives the statistical odds for the stock ahead of earnings. Contact our support team if you have any enquiries about any of our products. Call: (856) 848-8698. Email: info@akersbio.com
14 May 2020 Akers Biosciences Announces $4.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules. 14 May 2020 Akers Biosciences and Premas Biotech Announce Successful Completion of Vaccine Prototype & Obtained First Images of VLP
Akers Biosciences (AKER) reports earnings on 8/14/2020. The Earnings Whisper Score gives the statistical odds for the stock ahead of earnings. Contact our support team if you have any enquiries about any of our products. Call: (856) 848-8698. Email: info@akersbio.com Akers Biosciences, Inc. (the “Company”) (AKER), a developer of rapid health information technologies, today announced that Premas Biotech, its partner in the development of a vaccine candidate 亿帆医药（个股资料 操作策略 盘中直播 独家诊股）. 亿帆医药事件点评:并购NovoTek,国际化进展再露峥嵘. 亿帆医药 002019. 研究机构：东兴证券 分析 BD Biosciences provides flow cytometers, reagents, tools, and a wide range of services to support the work of researchers and clinicians who understand disease and improve care.
提供呼吸酒精偵測器及呼吸酮失重監控裝置等一次性使用之診斷檢測裝置公司Akers Biosciences Inc(AKER.US)成立於1989年，總部位於紐澤西州Thorofare，連同其
Akers Biosciences Aktie im Überblick: Realtimekurs, Chart, Fundamentaldaten, sowie aktuelle Nachrichten und Meinungen. 14 May 2020 Akers Biosciences Announces $4.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules. 14 May 2020 Akers Biosciences and Premas Biotech Announce Successful Completion of Vaccine Prototype & Obtained First Images of VLP Akers Bio develops, manufactures, and supplies rapid, point-of-care screening and testing products designed to bring health-related information directly to the patient or clinician in a timely and cost-efficient manner. All of Akers Bio’s rapid, single-use tests are performed in vitro (outside the body) and are Akers Biosciences Inc. Akers Biosciences, Inc. engages in the development, manufacture, and supply of screening and testing products. Its products include clinical diagnostics and safety tests. Akers Biosciences Inc. all SEC filings breakout by MarketWatch. View the AKER U.S. Securities and Exchange Commission reporting information. Stock analysis for Akers Biosciences Inc (AKER:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
新浪财经-美股频道为您提供aker(aker)股票股价,股票实时行情,新闻,财报,美股实时交易数据,研究报告,评级,财务指标分析等与aker(aker)股票相关的信息与服务
Shares of Akers Biosciences Inc. (NASDAQ:AKER) surged 15.8% to close at $3.22 following the completion of a clinical trial on the company's Chlamydia rapid 由专业分析师提供的Akers Biosciences(AKER)股票分析报告，千股千评。包括行情 走势分析，股价预测，精准股评，投资策略分析及股票买卖操作建议。
提供呼吸酒精偵測器及呼吸酮失重監控裝置等一次性使用之診斷檢測裝置公司Akers Biosciences Inc(AKER.US)成立於1989年，總部位於紐澤西州Thorofare，連同其
Akers Biosciences, Inc. (the “Company”) (AKER), a developer of rapid health information technologies, today announced that Premas Biotech, its partner in the development of a vaccine candidate 亿帆医药（个股资料 操作策略 盘中直播 独家诊股）. 亿帆医药事件点评:并购NovoTek,国际化进展再露峥嵘. 亿帆医药 002019. 研究机构：东兴证券 分析 BD Biosciences provides flow cytometers, reagents, tools, and a wide range of services to support the work of researchers and clinicians who understand disease and improve care. Shares of Akers Biosciences Inc. (NASDAQ:AKER) surged 15.8% to close at $3.22 following the completion of a clinical trial on the company's Chlamydia rapid 由专业分析师提供的Akers Biosciences(AKER)股票分析报告，千股千评。包括行情 走势分析，股价预测，精准股评，投资策略分析及股票买卖操作建议。 提供Akers Biosciences Inc(AKER)股票的行情走势、五档盘口、逐笔交易等实时行情 数据，及Akers Biosciences Inc(AKER)的资讯、公司公告、研究报告、行业研